Oral Clay–Antibiotic Complexes for Local H. pylori Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for clarithromycin-resistant Helicobacter pylori are ineffective and cause systemic antibiotic exposure, leading to side effects and burden on patients, as antibiotics are absorbed in the intestine and released through blood vessels to the gastric mucosa.
Innovation Solution
An orally-administered pharmaceutical composition comprising a complex of a non-absorbable antibiotic, such as gentamicin, and a clay mineral like smectite, which targets the gastric mucosa directly, minimizing systemic absorption and maximizing local antibiotic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are administered orally to eradicate H. pylori, then the antibiotic can reach the gastric mucosa, but the antibiotic is absorbed in the intestine and systemically exposed causing side effects and patient burden
Solution Approach 1:
The patent uses a clay mineral carrier as an intermediary substance to deliver the antibiotic directly to the gastric mucosa. The clay mineral forms a complex with the antibiotic, preventing intestinal absorption while enabling targeted delivery to the stomach lining where H. pylori resides, thus eliminating systemic exposure and side effects
Solution Approach 2:
The invention creates localized antibiotic action at the gastric mucosa by using the clay mineral-antibiotic complex. This complex remains confined to the gastrointestinal tract and releases antibiotic locally at the infection site without systemic distribution, achieving high local concentration while avoiding whole-body exposure
2Ease of operation
If standard triple therapy is used for H. pylori eradication, then treatment can be administered, but the eradication effect is currently very low at about 70%
Solution Approach 1:
The patent creates a composite material consisting of clay mineral and antibiotic in a specific complex structure. This composite enables the antibiotic to maintain stability in the gastric environment while providing sustained release directly at the infection site, significantly improving eradication effectiveness compared to conventional therapies
Solution Approach 2:
The invention changes the physical and chemical parameters of antibiotic delivery by forming a clay mineral complex. This complex alters the antibiotic's solubility, stability, and release characteristics, enabling it to withstand gastric acidity and release gradually at the target site, thereby enhancing eradication efficacy
3Reliability
If aminoglycosides are orally administered to treat H. pylori, then the antibiotic can reach the gastric mucosa, but aminoglycosides are almost not absorbed in the gastrointestinal tract and have been used only parenterally
Solution Approach 1:
The clay mineral serves as a mediator that enables oral administration of aminoglycosides. The clay-antibiotic complex protects the aminoglycoside from degradation in the gastrointestinal tract and facilitates its transport to the gastric mucosa, converting an injection-only antibiotic into an orally effective treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively eradicates clarithromycin-resistant Helicobacter pylori by attaching to the gastric mucosa, reducing side effects and minimizing impact on intestinal bacteria, while maintaining a low minimum inhibitory concentration on the affected area.
Implementation Method 1
a complex of a non-absorbable antibiotic and a clay mineral
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed is an orally-administered pharmaceutical composition or kit for eradicating Helicobacter pylori comprising a complex of a non-absorbable antibiotic and a clay mineral. The pharmaceutical composition or kit of the present disclosure may further comprise a β-lactam antibiotic and/or a gastric acid-suppressive agent.